Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 9, 2015, Pages F993-F1003

  Kim, Su Mi ^a   Lee, Sang Ho ^a   Kim, Yang Gyun ^a   Kim, Se Yun ^a   Seo, Jung Woo ^a   Choi, Young Wook ^a   Kim, Dong Jin ^a   Jeong, Kyung Hwan ^a   Lee, Tae Won ^a   Ihm, Chun Gyoo ^a   Won, Kyu Yeoun ^b   Moon, Ju Young ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Diabetic nephropathy; Macrophage; NLRP3 inflammasome; Uric acid

Indexed keywords

ALBUMIN; ALLOPURINOL; CHEMOKINE RECEPTOR CXCR4; CRYOPYRIN; FRUCTOSE; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PROBENECID; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; SUPEROXIDE; URIC ACID; ANTIGOUT AGENT; AUTACOID; CARRIER PROTEIN; CELL RECEPTOR; CXCL12 PROTEIN, HUMAN; HMGB1 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL1B PROTEIN, RAT; NLRP3 PROTEIN, HUMAN; NOD-LIKE RECEPTOR 3, RAT;

ACUTE MONOCYTIC LEUKEMIA; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC DIET; DIABETIC NEPHROPATHY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERURICEMIA; IMMUNOCYTOCHEMISTRY; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; LEUKEMIA CELL LINE; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URIC ACID BLOOD LEVEL; ANIMAL; CELL LINE; COCULTURE; COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

ANIMALS; CARRIER PROTEINS; CELL LINE; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GOUT SUPPRESSANTS; HMGB1 PROTEIN; HUMANS; HYPERURICEMIA; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; KIDNEY TUBULES, PROXIMAL; MACROPHAGES; MALE; NF-KAPPA B; RATS, INBRED OLETF; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; URIC ACID;

EID: 84930845012     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00637.2014     Document Type: Article

References (41)

1. Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem114: 525–531, 2013
2. Altemtam N, Russell J, El Nahas M. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant27: 1847–1854, 2012
3. Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab13: 11–22, 2011
4. Bakker PJ, Butter LM, Claessen N, Teske GJ, Sutterwala FS, Florquin S, Leemans JC. Atissue-specific role for Nlrp3 in tubular epithelial repair after renal ischemia/reperfusion. Am J Pathol184: 2013–2022, 2014
5. Bakker PJ, Butter LM, Kors L, Teske GJ, Aten J, Sutterwala FS, Florquin S, Leemans JC. Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation. Kidney Int85: 1112–1122, 2014
6. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med336: 1066–1071, 1997
7. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med353: 2450–2461, 2005
8. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol10: 826–837, 2010
9. Chen L, Zhang J, Zhang Y, Wang Y, Wang B. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res57: 199–204, 2008
10. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int65: 116–128, 2004
11. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens26: 269–275, 2008
12. Hotamisligil GS. Inflammation and metabolic disorders. Nature444: 860–867, 2006
13. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol16: 3553–3562, 2005
14. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev19: 265–271, 2011
15. Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE, Kim HW, Cha JJ, Hyun YY, Han SY, Han KH, Han JY, Cha DR. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PloS One8: e62068, 2013
16. Kim SM, Choi YW, Seok HY, Jeong KH, Lee SH, Lee TW, Ihm CG, Lim SJ, Moon JY. Reducing serum uric acid attenuates TGF-beta1- induced profibrogenic progression in type 2 diabetic nephropathy. Nephron Exp Nephrol121: e109–e121, 2012
17. Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, Forbes JM. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol15: 2139–2151, 2004
18. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes62: 194–204, 2013
19. Lee SH, Lee TW, Ihm CG, Kim MJ, Woo JT, Chung JH. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation. Nephrology10, Suppl: S32–S36, 2005
20. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: a three years of randomized parallel-controlled study. Clin Endocrinol (Oxf). [Epub ahead of print]
21. Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant29: 41–48, 2014
22. Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A, Consortium P. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep13: 550–559, 2013
23. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature440: 237–241, 2006
24. Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, Parente E, Mancina R, Netti GS, Becherucci F, Gacci M, Carini M, Gesualdo L, Rotondi M, Maggi E, Lasagni L, Serio M, Romagnani S, Romagnani P. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med205: 479–490, 2008
25. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant19: 2505–2512, 2004
26. Moon JY, Jeong KH, Lee TW, Ihm CG, Lim SJ, Lee SH. Aberrant recruitment and activation of T cells in diabetic nephropathy. Am J Nephrol35: 164–174, 2012
27. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, Choi AM. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol12: 222–230, 2011
28. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet375: 2161–2167, 2010
29. Rabadi MM, Kuo MC, Ghaly T, Rabadi SM, Weber M, Goligorsky MS, Ratliff BB. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol Renal Physiol302: F730–F741, 2012
30. Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci69: 2999–3013, 2012
31. Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, Johnson RJ. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol121: e71–e78, 2012
32. Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders HJ. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia52: 2445–2454, 2009
33. Shahzad K, Bock F, Dong W, Wang H, Kopf S, Kohli S, Al-Dabet MM, Ranjan S, Wolter J, Wacker C, Biemann R, Stoyanov S, Reymann K, Soderkvist P, Gross O, Schwenger V, Pahernik S, Nawroth PP, Grone HJ, Madhusudhan T, Isermann B. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int87: 74–84, 2015
34. Shigeoka AA, Mueller JL, Kambo A, Mathison JC, King AJ, Hall WF, Correia Jda S, Ulevitch RJ, Hoffman HM, McKay DB. An inflammasome- independent role for epithelial-expressed Nlrp3 in renal ischemia- reperfusion injury. J Immunol185: 6277–6285, 2010
35. Shikata K, Makino H. Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol46–54, 2001
36. Tian S, Zhang L, Tang J, Guo X, Dong K, Chen SY. HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. Am J Physiol Renal Physiol308: F69–F75, 2015
37. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol21: 1732–1744, 2010
38. Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, Bracey NA, Trpkov K, Bonni S, Duff HJ, Beck PL, Muruve DA. Inflammasome- independent NLRP3 augments TGF-beta signaling in kidney epithelium. J Immunol190: 1239–1249, 2013
39. Zhang C, Boini KM, Xia M, Abais JM, Li X, Liu Q, Li PL. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension60: 154–162, 2012
40. Zhuang Y, Ding G, Zhao M, Bai M, Yang L, Ni J, Wang R, Jia Z, Huang S, Zhang A. NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function. J Biol Chem289: 25101–25111, 2014
41. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care35: 99–104, 2012.